<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02773628</url>
  </required_header>
  <id_info>
    <org_study_id>AK/15-12-127/4581</org_study_id>
    <nct_id>NCT02773628</nct_id>
  </id_info>
  <brief_title>Impact of Reduction of Dust Mite Allergenic Load on Step Down of Inhaled Corticosteroids in Stable Asthma</brief_title>
  <official_title>Impact of Reduction of Dust Mite Allergenic Load on Step Down of Inhaled Corticosteroids in Stable Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire Saint Pierre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire Saint Pierre</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Eviction methods for dust mite allergy have been evaluated in asthma control in a recent
      Cochrane meta-analysis. None have shown efficacy on asthma control and there are not
      recommended. The purpose is to evaluate the efficacy of a new commercialized system (Acar'Up)
      to decrease dust mite load and to assess its impact on the possibility to perform inhaled
      corticosteroids step down in stable asthmatics.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eviction methods for dust mite allergy have been evaluated in asthma control in a recent
      Cochrane meta-analysis. None have shown efficacy on asthma control and there are not
      recommended. The purpose is to evaluate the efficacy of a new commercialized system, Acar'Up
      (a spray pulverized on a technical textile that traps the dust mite) to decrease dust mite
      load and to assess its impact on the possibility to perform inhaled corticosteroids step down
      in stable asthmatics.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    methodological concerns about study design
  </why_stopped>
  <start_date>May 2016</start_date>
  <completion_date type="Actual">August 2018</completion_date>
  <primary_completion_date type="Actual">August 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>assessment of successful stepdown of inhaled corticosteroid using clinical evaluation</measure>
    <time_frame>4 months</time_frame>
    <description>assessment of the successful step down of inhaled corticosteroid using clinical evaluation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>assessment of successful stepdown of inhaled corticosteroid using asthma scale: asthma control questionnaire (ACQ)</measure>
    <time_frame>4 months</time_frame>
    <description>assessment of the successful step down of inhaled corticosteroid using asthma scale: asthma control questionnaire (ACQ)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>assessment of successful stepdown of inhaled corticosteroid using asthma quality of life questionnaire (AQLQ)</measure>
    <time_frame>4 months</time_frame>
    <description>assessment of the successful step down of inhaled corticosteroid using asthma quality of life questionnaire (AQLQ)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>assessment of asthma control by the asthma control questionnaire questionnaire</measure>
    <time_frame>4 months</time_frame>
    <description>by the asthma control questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>assessment of asthma quality of life by the asthma quality of life questionnaire</measure>
    <time_frame>4 months</time_frame>
    <description>by the asthma quality of life questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>assessment of rhinitis control by the rhinitis quality of life questionnaire</measure>
    <time_frame>4 months</time_frame>
    <description>by the rhinitis quality of life questionnaire</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>stable asthmatics receiving an Acar'up placebo system</description>
  </arm_group>
  <arm_group>
    <arm_group_label>treatment group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>stable asthmatics receiving Acar'up system</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Acar'up system</intervention_name>
    <arm_group_label>treatment group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Acar'up placebo system</intervention_name>
    <arm_group_label>control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  confirmed asthma diagnosis

          -  controlled asthma for more than 3 months

          -  treatment with inhaled corticosteroids

          -  dust mite allergy proved by skin tests ou specific immunoglobulin E

        Exclusion Criteria:

          -  chronic obstructive pulmonary disease, bronchiectasis, Fibrosis, tuberculosis

          -  asthma-chronic obstructive pulmonary disease overlap syndrome

          -  ongoing desensitization for dust mite

          -  pregnancy

          -  previous use of Acar'up
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>CHu Saint Pierre</name>
      <address>
        <city>Brussels</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>April 25, 2016</study_first_submitted>
  <study_first_submitted_qc>May 13, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 16, 2016</study_first_posted>
  <last_update_submitted>February 7, 2019</last_update_submitted>
  <last_update_submitted_qc>February 7, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

